Advancements in Artificial Heart Technology and Etiology, Pathophysiology, Diagnosis, Differential Diagnosis, Treatment as well as Complications of Cardiovascular Diseases

In recent years, the field of Cardiovascular medicine has witnessed groundbreaking advancements in artificial heart technology. Early iterations of artificial hearts faced significant challenges, along with issues related to biocompatibility, durability and size. One notable example of a breakthrough in artificial hear technology is the development of Syncardia temporary Total Artificial Heart (TAH), which received FDA approval in 2004. Moreover, advancements in materials science and biocompatible coatings have contributed to the development of artificial hearts with improved longevity and reduced risk of complications, such as thrombosis and infection. Finally, it is concluded that artificial hearts represents a paradigm shift in the treatment of Cardio vascular disease, offering hope to individuals with end _ stage heart failure who would otherwise face limited options for survival.